The schematics below show how an ImmTAC molecule works. In the first step, ImmTAC molecules recognise and strongly bind to cancer cells displaying a particular target (peptide-HLA) (1). Circulating T cells are then recruited to the tumour site by interacting with the free end of the ImmTAC molecule (an anti-CD3 antibody fragment) (2). The ImmTAC molecule acts as a bridging molecule between the cancer cell and the T cell, enabling the formation of a perfectly optimised immune synapse (3). The redirected T cell is then activated and able to release its load of cancer cell killing lytic granules, leading to destruction of the cancer (4).
The videos below show real cancer cells being killed by ImmTAC-redirected T cells, the schematics on the right show the different cell types that can be seen in each video.
Here, ImmTAC-redirected non-cancer specific T cells (shown in blue) kill the cancer cells (shown in red), leaving adjacent non-cancerous cells (shown in green) intact.
Here, a single ImmTAC-redirected non-cancer specific T cell (shown in blue) kills multiple cancer cells (shown in red) through serial killing.